Safety Assessment of Inactivated Whole Virion Booster Vaccine against the SARS­-CoV-­2 Virus (BelCovidVac) in Immunized Study Subjects aged 18 to 60 Years (day 28)

Relevance. According to the World Health Organization (WHO), it is not yet possible to effectively stop the spread of new strains of coronavirus [1]. At the same time, most experts and analysts in the field of medicine publicly admit that at the moment vaccination is the most powerful weapon in the fight against COVID-19 [2–6]. While vaccination, like the entire health care system, has now become an element of politics and economics, the creation of proprietary vaccine in each country has become an element of national security [7]. Aims. To evaluate the safety of the inactivated booster vaccine «BelCovidVac» in immunized study subjects from 18 to 60 years old (day 28). Materials and methods. A prospective, randomized, double-blind phase I/II trial evaluated the safety of an inactivated whole virion booster vaccine against the SARS-CoV-2 virus in two doses in healthy study subjects aged 18 to 60 years who had completed a full course of vaccination with the SARS-CoV-2 virus and/or recovered from COVID-19, which included 129 subjects (24 in phase 1 and 105 in phase 2). Results. The study reported 195 adverse reactions in 94 study subjects. The study reported 80 adverse reactions in 24 (100%) study subjects at Phase 1, and 115 adverse reactions in 70 subjects at Phase 2. The study detected mild adverse reactions in 77,50% of cases at Phase 1, and in 71,30% at Phase 2. Moreover, the study found one serious adverse reaction in 1 subject at Phase 2, which occurred as a result of taking placebo. The incidence of adverse reactions with the use of the candidate vaccine in two doses is comparable to placebo (χ² = 3,15, p = 0,08). Conclusion. The vaccine candidate demonstrated good tolerability at both Phase 1 and Phase 2.

1. World Health Organization. Coronavirus disease (COVID-19), 2023, [Electronic resource]. [date of access 2024 April 07]. Available at: https://www.who.int/news-room/fact-sheets/detail/coronavirus-disease-(covid-19)

2. Thanh Le T, Andreadakis Z, Kumar A, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020 May;19(5):305–306. DOI: https://doi.org/10.1038/d41573-020-00073-5

3. Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020 Oct; 586(7830):516–527. DOI: https://doi.org/10.1038/s41586-020-2798-3

4. Gates B. Responding to Covid-19 - A Once-in-a-Century Pandemic? N Engl J Med. 2020 Apr 30;382(18):1677-1679. DOI: https://doi.org/10.1056/NEJMp2003762

5. World Health Organization. COVID-19 Vaccines Advice, 2023, [Electronic resource] [date of access 2024 April 07]. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/advice

6. Fitzpatrick M, Moghadas S, Pandey A, Galvani A. Two years of U.S. COVID-19 vaccines have prevented millions of hospitalizations and deaths, to the point. New York, NY: The Commonwealth Fund; 2022. [date of access 2024 April 07]. Available at: https://www.commonwealthfund.org/blog/2022/two-years-covid-vaccines-prevented-millions-deaths-hospitalizations

7. Pinevich DL. Creating your own vaccine is an element of national security, 2020. [date of access 2024 April 07]. Available at: https://news.sb.by/articles/pinevich-sozdanie-sobstvennoy-vaktsiny-eto-element-natsionalnoy-bezopasnosti.html (In Russ.).

8. Decision of the Council of the Eurasian Economic Commission «On approval of the Rules of Good Clinical Practice of the Eurasian Economic Union», November 3, 2016 No. 79. [date of access 2024 April 07]. Available at: https://pravo.by/document/?guid=3871&p0=F91600334 (In Russ.).

9. Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products (europa.eu) [Electronic resource] 20 July 2017 EMEA/CHMP/SWP/28367/07 Rev.1 Committee for Medicinal Products for Human Use (CHMP). [date of access 2024 апрель 07]. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-strategies-identify-and-mitigate-risks-first-human-and-early-clinical-trials-investigational-medicinal-products-revision-1_en.pdf

10. ТКП 030-2017 (33050) «Good Manufacturing Practices» 2017. [date of access 2024 April 07]. Available at: https://minzdrav.gov.by/upload/dadvfiles/000394_325766_TKP_0302017_33050.pdf (In Russ.).

11. MedDRA. Medical dictionary of medical terminology. Version 26.01.2023. [date of access 2024 April 07]. Available at: https://www.meddra.org/ (In Russ.).

12. Pinevich DL. Creating your own vaccine is an element of national security, 2020. [date of access 2024 April 07]. Available at: https://news.sb.by/articles/pinevich-sozdanie-sobstvennoy-vaktsiny-eto-element-natsionalnoy-bezopasnosti.html (In Russ.).